OncoMatch/Clinical Trials/NCT06544265
SynKIR-310 for Relapsed/Refractory B-NHL
Is NCT06544265 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies SynKIR-310 for b cell lymphoma.
Treatment: SynKIR-310 — This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refractory B-NHL.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: car-t cell therapy
Cannot have received: investigational agent
Exception: within 30 days prior to screening
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Colorado Blood Cancer Institute, part of Sarah Cannon Cancer Institute · Denver, Colorado
- Winship Cancer Institute of Emory University · Atlanta, Georgia
- The University of Kansas Cancer Center · Fairway, Kansas
- Rutgers Cancer Institute · New Brunswick, New Jersey
- Abramson Cancer Center of the University of Pennsylvania · Philadelphia, Pennsylvania
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06544265 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior investigational agent disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify